Exploiting Nanoparticles for Blood-Brain Barrier Permeation: A Promising Paradigm in Neurotherapeutics

Particle size

Smaller particles shown that they are capable of pass through the cell membranes with relative ease when compared with the larger particles. Recent studies shown that the Insulin targeted gold nanoparticles with relatable <20nm diameter are ease in biocompatibility and bioavailability [6].

Small Particle Size: Nanoparticles should be on the Nano scale (typically less than 200 nanometers) to facilitate their penetration through the tight junctions of the BBB [7].

Biocompatibility: The nanoparticles should be non-toxic and biocompatible to avoid adverse reactions or damage to brain tissue.

Surface Functionalization: Surface modifications with appropriate ligands or targeting moieties are essential to enhance the nanoparticles’ ability to bind to specific receptors on the BBB, increasing their chances of transport into the brain [8].

Stability: Nanoparticles should maintain their structural integrity and drug-loading capacity during circulation and transport through the bloodstream to reach the brain.

Drug Loading Capacity: The nanoparticles should efficiently encapsulate and protect the therapeutic agent, ensuring its stability and controlled release within the brain [9].

Controlled Release: The ability to release the drug in a controlled and sustained manner is critical to optimize therapeutic efficacy while minimizing side effects.

Transport Mechanisms: Effective nanoparticles can exploit various transport mechanisms, including receptor-mediated transcytosis, adsorptive-mediated transcytosis, or passive diffusion, to traverse the BBB [10].

Protection from Enzymatic Degradation: Nanoparticles should shield the loaded drug from degradation by enzymes in the bloodstream and brain tissue.

Long Circulation Time: Prolonged circulation in the bloodstream allows nanoparticles to maximize their chances of crossing the BBB, so they should evade rapid clearance by the reticuloendothelial system [11].

Selective Targeting: The ability to target specific cells or regions within the brain is advantageous to ensure precise drug delivery and minimize off-target effects.

Biodegradability: Biodegradable nanoparticles are advantageous as they can be broken down and excreted from the body after drug release, reducing potential long-term accumulation.

Non-Immunogenic: The nanoparticle system should not trigger a significant immune response to avoid complications and ensure long-term application.

Scalability: The manufacturing process for these nanoparticles should be scalable to meet the demands of large-scale production for clinical applications [12].

Stability under Storage Conditions: Maintaining stability and drug-loading capacity during storage is crucial to ensure the product’s efficacy over time.

Regulatory Compliance: The nanoparticle DDS (Drug Delivery System) should meet regulatory standards for safety and efficacy to facilitate its approval for clinical use. Developing nanoparticle drug delivery systems that embody these characteristics is crucial for the successful treatment of neurological disorders and represents a promising avenue for advancing neurotherapeutics [13].

Trancytosis – and Entry Portal System into the CNS

As evidence shown that the blood–brain barrier is usually as the most effective entry route for nanoparticles as it presents the largest surface area between the periphery and the CNS (∼20 m2), is the major access point for most endogenous molecules, and provides the most direct access route to cellular targets in the interstitial fluid [14]. Recently, a transport route that permits endogenous macromolecules, such as proteins and lipoproteins, to cross the blood–brain barrier endothelial cells has gained wide- scale interest in nanoparticle delivery to the CNS. This transport route, called transcytosis, involves endocytosis into a transport vesicle that is trafficked across the cell to the opposite membrane, where it is fuses and the cargo is released unaltered [13].

Transcytosis is a fundamental cellular process involved in the movement of substances across the blood-brain barrier (BBB) and the uptake of nanoparticles into the brain. Nanoparticles, due to their unique properties and engineered characteristics, can exploit transcytosis mechanisms to traverse the BBB, allowing for the delivery of therapeutic agents or diagnostic tools to the brain.

The Process Involves the Following Steps

Endocytosis ate the luminal site by nanoparticles are often functionalized with ligands or surface modifications that enable them to interact with specific receptors on the luminal (blood-facing) side of brain endothelial cells that make up the BBB. These ligands can mimic the natural ligands that the endothelial cells would typically recognize. Vesicle formation happens by when nanoparticles bind to these receptors, the endothelial cells engulf the nanoparticles through receptor-mediated endocytosis [13, 14]. This process results in the formation of vesicles, which encapsulate the nanoparticles. Transcytosis across Endothelial Cells as vesicles carrying the nanoparticles move through the cytoplasm of the endothelial cells towards the abluminal (brain-facing) side. This process can involve passing through multiple cellular compartments. Exocytosis at the abluminal side, the vesicles containing nanoparticles are subjected to exocytosis, releasing the nanoparticles into the brain’s interstitial fluid. This allows the nanoparticles to access the neural tissue and interact with specific brain cells or structures [15]. And distributed in the central nervous system (CNS), the nanoparticles can be designed to disperse to their intended target, whether it is a specific brain region, cell type, or pathological site. This can be achieved through various surface modifications and targeting ligands on the nanoparticles.

Transcytosis related to the blood brain barrier by receptor mediated transcytosis

On the luminal (blood-facing) side of the brain endothelial cells interact with specific ligands, allowing them to be internalized and transported across the cell. On the abluminal (brain-facing) side, these vesicles can undergo exocytosis to release the transported substances into the brain tissue [16] (Figure 1).

Click to enlarge

Ligand-Receptor Interaction: Receptor-mediated transcytosis begins with the interaction between ligands on the surface of nanoparticles or therapeutic agents and specific receptors expressed on the luminal side of brain endothelial cells. These receptors are typically responsible for the transport of essential molecules such as nutrients, hormones, or carrier proteins [17].

Vesicle Formation: When ligands on the nanoparticles bind to their respective receptors, the endothelial cells undergo endocytosis. This results in the formation of vesicles containing the nanoparticles. These vesicles encapsulate the therapeutic agents and are internalized into the endothelial cells [18].

Intracellular Transport: The vesicles, loaded with nanoparticles and therapeutic agents, are transported within the endothelial cells’ cytoplasm. This intracellular transport can involve the movement of vesicles along microtubules and other cellular structures [19].

Exocytosis: The vesicles containing the nanoparticles are transported through the endothelial cells and released on the abluminal (brain-facing) side of the BBB. This process is known as exocytosis, and it results in the release of therapeutic agents into the brain’s interstitial fluid [20]. Exocytosis is the fusion of an intracellular vesicle with the plasma membrane. Constitutive exocytosis occurs in all cell types as a means for cells to recycle lipids and proteins to the plasma membrane and is very slow. In specialized cells such as neurons, there is additionally a highly regulated form of exocytosis that synchronously releases many vesicles of intracellular contents into the extracellular environment on a millisecond scale [21]. Here, the final steps of fusion between the vesicular and target plasma membrane are under strict temporal control by specialized proteins that also provide the energy for fast fusion.

Distribution within the CNS: Once in the CNS, the nanoparticles and their therapeutic cargo can disperse to their intended target sites within the brain. The selective nature of RMT ensures that the therapeutic agents are transported to specific regions or cell types-9 [22].